Compare McKesson Corporation (MCK) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Phillips 66 — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: McKesson Corporation and Phillips 66 are close in size by market cap, and Phillips 66 pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Phillips 66 for 62 Days on average.
| MCK | PSX | |
|---|---|---|
Market Cap | $108.46B | $112.36B |
Volume | 712,607 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $995.69 | $281.60 |
52-Week Low | $725.17 | $126.76 |
Typical Hold Time | 74 Days | 62 Days |
Enterprise Value | $115.00B | $128.83B |
Dividend Yield | 0.4% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Phillips 66 (PSX) trades at $278.18, up 2.42% with strong technical momentum as it approaches resistance near $280. The stock shows robust fundamentals with a P/E of 16.07 and ROE of 24.02%, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI-driven operational improvements, while analyst consensus remains bullish with a $279 price target.
PSX offers attractive valuation metrics and strong profitability, though revenue declines from 2022-2025 present headwinds. Key risks include refining margin volatility and potential diesel export restrictions. With institutional support and positive earnings trajectory, the stock presents a compelling opportunity for value-oriented investors despite cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
